Rates of first serious infection were 1.7–3.5 per 100 patient-years in TNFα-inhibitor therapies, with increasing age and high-dose glucocorticoids (>35 mg/week) being a major risk factors for serious infections in the Hellenic Registry of Biologic Therapies.7 Similar rates of serious infections (2.3/100 patient-years) were reported in the the RA-WG cohort (Thomas K et al., unpublished data). This evidence concerns the gene TNF and infection.